Hierarchy of simulation models in predicting structure and energetics of the Src SH2 domain binding to tyrosyl phosphopeptides. 2002

Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, California 92121-1111, USA. verk@agouron.com

Structure and energetics of the Src Src Homology 2 (SH2) domain binding with the recognition phosphopeptide pYEEI and its mutants are studied by a hierarchical computational approach. The proposed structure prediction strategy includes equilibrium sampling of the peptide conformational space by simulated tempering dynamics with the simplified, knowledge-based energy function, followed by structural clustering of the resulting conformations and binding free energy evaluation of a single representative from each cluster, a cluster center. This protocol is robust in rapid screening of low-energy conformations and recovers the crystal structure of the pYEEI peptide. Thermodynamics of the peptide-SH2 domain binding is analyzed by computing the average energy contributions over conformations from the clusters, structurally similar to the predicted peptide bound structure. Using this approach, the binding thermodynamics for a panel of studied peptides is predicted in a better agreement with the experiment than previously suggested models. However, the overall correlation between computed and experimental binding affinity remains rather modest. The results of this study show that small differences in binding free energies between the Ala and Gly mutants of the pYEEI peptide are considerably more difficult to predict than the structure of the bound peptides, indicating that accurate computational prediction of binding affinities still remains a major methodological and technical challenge.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010748 Phosphopeptides PEPTIDES that incorporate a phosphate group via PHOSPHORYLATION. Phosphopeptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D013816 Thermodynamics A rigorously mathematical analysis of energy relationships (heat, work, temperature, and equilibrium). It describes systems whose states are determined by thermal parameters, such as temperature, in addition to mechanical and electromagnetic parameters. (From Hawley's Condensed Chemical Dictionary, 12th ed) Thermodynamic
D014443 Tyrosine A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin. L-Tyrosine,Tyrosine, L-isomer,para-Tyrosine,L Tyrosine,Tyrosine, L isomer,para Tyrosine
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies
D018909 src Homology Domains Regions of AMINO ACID SEQUENCE similarity in the SRC-FAMILY TYROSINE KINASES that fold into specific functional tertiary structures. The SH1 domain is a CATALYTIC DOMAIN. SH2 and SH3 domains are protein interaction domains. SH2 usually binds PHOSPHOTYROSINE-containing proteins and SH3 interacts with CYTOSKELETAL PROTEINS. SH Domains,SH1 Domain,SH2 Domain,SH3 Domain,src Homology Region 2 Domain,Homology Domain, src,Homology Domains, src,SH Domain,SH1 Domains,SH2 Domains,SH3 Domains,src Homology Domain

Related Publications

Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
December 1993, Molecular and cellular biology,
Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
April 1999, Biochemistry,
Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
April 1995, Proceedings of the National Academy of Sciences of the United States of America,
Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
March 2003, Bioorganic & medicinal chemistry letters,
Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
August 2009, Bioorganic chemistry,
Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
September 2008, Proteins,
Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
August 2000, Biochemistry,
Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
February 2002, Journal of molecular biology,
Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
May 1994, Biochemistry,
Gennady M Verkhivker, and Djamal Bouzida, and Daniel K Gehlhaar, and Paul A Rejto, and Lana Schaffer, and Sandra Arthurs, and Anthony B Colson, and Stephan T Freer, and Veda Larson, and Brock A Luty, and Tami Marrone, and Peter W Rose
November 2005, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!